End of Content.
EARLIER
Combined Screening + NT – High risk screen (>1:250) was followed by NIPT and in case of a high risk in NIPT, would be followed by QFPCR and KT.
PRESENT
We are proud to introduce to you the Microarray test in this package. Combined Screening + NT – High risk screen (>1:250) was followed by NIPT and in case of a high risk in NIPT, would be followed by QFPCR and Microarray (60K).
What is Microarray ?
Chromosomal Microarray (CMA) is an array-based molecular cytogenetic technique that can overcome some limitations of a karyotype, and is particularly useful for its ability to detect submicroscopic gains and losses on every chromosome. This technique compares the genomic content (DNA) of a patient (target) with that of a normal control individual (or indi- viduals) and detects gains and losses (duplications and deletions) ranging in size from very large, including aneuploidy of entire chromosomes, to very small loss or gain (typically as small as about 200,000 base pairs or 0.2 Mb).
CMA in Prenatal Settings
The American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal- Fetal Medicine recommend CMA as a replacement for the fetal karyotype in patients with a pregnancy demonstrating one or more major structural abnormalities on ultrasound when undergoing invasive prenatal diagnosis
- If maternal blood tests during pregnancy were abnormal, indicating an increased chance of a medical condition or birth defect
- If an abnormal finding is seen on ultrasound and other genetic testing has been normal
- The company's commitment to research-backed content, often supported by collaborations with reputable institutions, enhances reliability.
- If you previously had a child with a medical condition, particularly one associated with chromosomal changes
- In case of Recurrent Pregnancy Loss
- In case of advanced maternal age
Feature Test
Chromosomal Microarray optima (315K), Prenatal, Amniotic Fluid/ Chorionic Villus Sampling
Chromosomal Microarray optima (315K), Autopsy,Products of Conception, or Stillbirth
Chromosomal Microarray Cytosure (750K), Prenatal, Amniotic Fluid/Chorionic Villus Sampling
Chromosomal Microarray Cytosure (750K), Autopsy, Products of Conception, or Stillbirth
CMA in Pediatric Settings
The American College of Medical Genetics (ACMG)1,American Academy of Pediatrics (AAP)2 and the American Academy of Neurology (AAN)3 all recommend chromosomal microarray testing for individuals with one or more of the following:
- Developmental delays or intellectual disability
- Birth defects
- Unusual physical features
- Autism spectrum disorders CMA is also an appropriate follow-up test for individuals with congenital anomalies with a previously normal conventional chromosome study
Feature Test
Chromosomal Microarray Cytosure (750K,ostnatal, Peripheral Blood
Chromosomal Microarray Optima (315K),Postnatal, Peripheral Blood
Orbitoasia Diagnostics - Chromosomal Microarray Offerings
|
Parameters
|
Parameters
|
Cytoscan 750K
|
Cytoscan Optima
|
|---|---|---|---|
|
Where to be Used?
|
CytoScan HD
High-resolution analysis of CNVs
constitutional postnatal samples
|
Analysis of gains and loss for
constitutional postnatal samples
|
Detection of gross aneuploidies
at low cost and low resolution
|
|
Probe Details
|
High Density coverage with > 2.6
million probes
|
CNV Probes = 550,000
SNP Probes = 200,000 Total Probes = 750,000 |
CNV Probes = 18,018
SNP Probes = 148,450 Total Probes = 315,000 |
|
Sample Types
|
Blood, Buccal Swabs, Saliva,
fresh & frozen tissues, uncultured
or cultured cells, CVS ,
Amniocentesis,POC, etc.
|
Blood, Buccal Swabs, Saliva,
fresh & frozen tissues,
uncultured or cultured cells,
CVS, Amniocentesis, POC, etc.
|
Blood, Buccal Swabs, Saliva,
fresh & frozen tissues,
uncultured or cultured cells,
CVS , Amniocentesis,POC, etc
|
|
Analytical Claims
|
Gains < 10-25 Kb
Losses < 10-25 kb AOH> 1mb Mocaissim > ~ 15% |
Gains 200-400 kb
Losses 200-400 kb AOH> 5 mb Mocaissim > ~ 15-20% |
Gains 2 mb
Losses 1 mb AOH> ~5 mb Mocaissim > ~ 20% 396 genes at 25m/100kb |
Chromosomal Microarray Advantage
|
Karyotyping
|
FISH
|
Chromsomal Microarray
|
|---|---|---|
|
|
|
Recommendations
ACOG 2016
Most genetic changes identified by chromosomal microarray analysis that typically are not identified on standard karyotype are not associated with increasing maternal age: therefore, the use of this test can be considered for all women who undergo prenatal diagnostic testing, regardless of age. Prenatal chromosomal microarray analysis is recommended for a patient with a fetus with one or more major structural abnormalities identified on ultrasonographic examination and who is undergoing invasive prenatal diagnosis. This test typically can replace the need for fetel karyotype.
Society of Maternal & Fetal Medicine 2016
The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recommend that all pregnant women should be offered prenatal assessment for aneuploidy by screening or diagnostic testing regardless of maternal age or other risk factors. The differences between screening and diagnostic testing also should be discussed. SMFM recommends that CMA be offered when genetic analysis is performed in cases with fetal Structural anomalies and /or stillbirth and replaces the need for fetal karyotype in these cases.
For any further information, please fill in the form below and we will call you back shortly:
Frequently asked questions
Find answers to your lab service questions in our FAQ section
A microarray is a powerful tool used to analyze the expression of thousands of genes simultaneously. It consists of a grid of microscopic spots, each containing DNA or RNA probes. These probes can hybridize with target molecules, allowing the simultaneous analysis of gene expression or genetic variation.
Microarray analysis enables researchers to study gene expression patterns, identify genetic variations, and understand molecular mechanisms underlying diseases. It is invaluable for drug discovery, biomarker identification, and personalized medicine.
To initiate a microarray project, you can contact our customer support team through the contact information provided on our website. We will guide you through the process, including project consultation, sample submission, and project timeline.
Yes, our team of experts can collaborate with you to design your experiment, select the appropriate microarray platform, and provide comprehensive data analysis services. We strive to ensure that your research goals are met effectively.
Orbito Asia provides comprehensive microarray services, including gene expression profiling, SNP genotyping, and comparative genomic hybridization (CGH). Our services cater to diverse research needs in genomics and molecular biology.
Orbito Asia offers a range of microarrays, including DNA microarrays for genotyping and CGH, as well as RNA microarrays for gene expression profiling. We also provide custom microarray solutions to meet specific research requirements.
Absolutely. Our technical support team is available to assist you throughout the duration of your project and beyond. We are committed to ensuring that your experience with Orbito Asia is seamless and successful.
Turnaround time can vary depending on the specific scope and requirements of your project. Our team will provide you with a detailed timeline during the project initiation phase, taking into consideration factors such as sample size and complexity.
